Search

Your search keyword '"Verdoux, Helene"' showing total 164 results
Start Over Author "Verdoux, Helene"
164 results on '"Verdoux, Helene"'

55. Psychiatry Res

Author

VERDOUX, Helene, QUILES, C., CERVELLO, S., DUBREUCQ, J., BON, L., MASSOUBRE, C., POMMIER, R., LEGROS-LAFARGE, E., JAAFARI, N., GUILLARD-BOUHET, N., CHEREAU-BOUDET, I., COUHET, G., PLASSE, J., and FRANCK, N.

Published
2019

56. Schizophr Res

Author

VERDOUX, Helene, QUILES, C., and DE LEON, J.

Published
2019

67. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database

Author

Billioti de Gage, Sophie, Collin, C., Le-Tri, T., Pariente, Antoine, Begaud, Bernard, Verdoux, Helene, Dray-Spira, R., Zureik, M., Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Agence nationale de sécurité du médicament et des produits de santé [Saint-Denis] (ANSM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), and Admin, Oskar

Subjects
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Abstract

International audience; BACKGROUND: Hepatotoxicity may be a concern when prescribing antidepressants. Nevertheless, this risk remains poorly understood for serotonin and noradrenaline reuptake inhibitors (SNRIs: venlafaxine, milnacipran, duloxetine) and 'other antidepressants' (mianserin, mirtazapine, tianeptine and agomelatine), particularly in comparison with selective serotonin reuptake inhibitors (SSRIs: fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, escitalopram), which are by far the most commonly prescribed antidepressants.OBJECTIVE: We quantified the risk of serious liver injury associated with new use of SNRIs and 'other antidepressants' compared with SSRIs in real-life practice.METHODS: Based on the French national health insurance database, this cohort study included 4,966,825 individuals aged 25 years and older with a first reimbursement of SSRIs, SNRIs or 'other antidepressants' between January 2010 and June 2015. We compared the risk of serious liver injury within the 6 months following antidepressant initiation according to antidepressant class, with SSRIs as the reference, using an inverse probability-of-treatment-weighted Cox proportional hazard model adjusted for demographic characteristics and risk factors of liver injury. RESULTS: We identified 382 serious liver injuries overall (none for milnacipran initiators). Age and gender standardized incidence rates per 100,000 person-years were 19.2 for SSRIs, 22.2 for venlafaxine, 12.6 for duloxetine, 21.5 for mianserin, 32.8 for mirtazapine, 31.6 for tianeptine and 24.6 for agomelatine initiators. Initiation of antidepressants of interest versus SSRIs was not associated with an increased risk of serious liver injury [adjusted hazard ratios (95% confidence interval): venlafaxine 1.17 (0.83-1.64), duloxetine 0.54 (0.28-1.02), mianserin 0.90 (0.58-1.41), mirtazapine 1.17 (0.67-2.02), tianeptine 1.35 (0.82-2.23) and agomelatine 1.07 (0.51-2.23)]. This finding was confirmed by the results of an additional study using a case-time-control design.CONCLUSION: These results do not provide evidence of an increased risk of serious liver injury following initiation of SNRIs or 'other antidepressants' compared with SSRIs in real-life practice. This could reflect an inherent lack of difference in risk between the drug classes, or the fact that individuals with higher susceptibility to drug-induced liver injury are not prescribed drugs considered to be more hepatotoxic.

Published
2018

68. Agitation et délire aigu: Rev Prat

Author

VERDOUX, Helene, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
PharmacoEpi-Drugs, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Published
2018

79. The use of random-effects models to identify health care center-related characteristics modifying the effect of antipsychotic drugs

Author

Nordon,Clementine, Battin,Constance, Verdoux,Helene, Haro,Josep Maria, Belger,Mark, Abenhaim,Lucien, van Staa,Tjeerd, Nordon,Clementine, Battin,Constance, Verdoux,Helene, Haro,Josep Maria, Belger,Mark, Abenhaim,Lucien, and van Staa,Tjeerd

Abstract

Clementine Nordon,1 Constance Battin,1 Helene Verdoux,2 Josef Maria Haro,3 Mark Belger,4 Lucien Abenhaim,1 Tjeerd Pieter van Staa5 On behalf of the IMI GetReal WP2 Group 1Epidemiological Research, Analytica LASER, Paris, 2Population Health Research Center, Team Pharmaco-Epidemiology, UMR 1219, Bordeaux-2 University, INSERM, Bordeaux, France; 3Parc Sanitari Sant Joan de Deu, CIBERSAM, University of Barcelona, Barcelona, Spain; 4Eli Lilly and Company Limited, Erl Wood Manor, Windlesham, 5Farr Institute, University of Manchester, Manchester, UK Purpose: A case study was conducted, exploring methods to identify drugs effects modifiers, at a health care center level.Patients and methods: Data were drawn from the Schizophrenia Outpatient Health Outcome cohort, including hierarchical information on 6641 patients, recruited from 899 health care centers from across ten European countries. Center-level characteristics included the following: psychiatrist’s gender, age, length of practice experience, practice setting and type, countries’ Healthcare System Efficiency score, and psychiatrist density in the country. Mixed multivariable linear regression models were used: 1) to estimate antipsychotic drugs’ effectiveness (defined as the association between patients’ outcome at 3 months – dependent variable, continuous – and antipsychotic drug initiation at baseline – drug A vs other antipsychotic drug); 2) to estimate the similarity between clustered data (using the intra-cluster correlation coefficient); and 3) to explore antipsychotic drug effects modification by center-related characteristics (using the addition of an interaction term).Results: About 23% of the variance found for patients’ outcome was explained by unmeasured confounding at a center level. Psychiatrists’ practice experience was found to be associated with patient outcomes (p=0.04) and modified the relative

Published
2017

82. Les thymorégulateurs (collection Psychiatrie)

Author

VERDOUX Hélène and VERDOUX Hélène

Subjects
Antipsychotic drugs
Abstract

La classe des médicaments thymorégulateurs s'est longtemps résumée au seul lithium, avant de s'élargir aux anticonvulsivants. Plus récemment, avec les modifications intervenues dans le profil des molécules regroupées dans cette classe médicamenteuse et la remise en cause de la distinction entre antipsychotiques et thymorégulateurs, différentes définitions ont émergé, selon les critères retenus et l'accent sur l'efficacité préventive ou curative. Ces interrogations sur la définition de la classe des thymorégulateurs s'accompagnent d'un questionnement sur l'évolution des modèles nosographiques et donc des stratégies thérapeutiques. Ainsi l'ouvrage a-t-il pour objectif d'apporter les informations nécessaires à une prescription raisonnée de thymorégulateurs : - les bases fondamentales : mécanismes neurobiologiques, pharmacocinétique, pharmacodynamie, pharmacogénétique, effets sur les processus cognitifs et émotionnels ; - les modalités de prescription : incluant l'instauration, la surveillance, l'arrêt du traitement ainsi que les effets secondaires et les complications, pour le lithium, les anticonvulsivants et les antipsychotiques ; - l'éducation thérapeutique du patient. - les indications : trouble bipolaire, dépression, troubles psychotiques, troubles de la personnalité, addictions, prescriptions dimensionnelles ; - les spécificités liées aux populations et aux situations : association de plusieurs thymorégulateurs ou à un antidépresseur ou à l'ECT, utilisation chez les enfants et les adolescents, chez la femme enceinte ou allaitant, chez les personnes âgées. Réunissant une cinquantaine de spécialistes reconnus, riche d'une trentaine de tableaux et schémas explicatifs et d'un index détaillé, cet ouvrage est la référence indispensable pour tous les praticiens devant prescrire des thymorégulateurs.

Published
2013

83. Auteurs

Author

Abdel-Baki, Amal, Amado, Isabelle, Arfeuillère, Sophie, Arnaud, Ingrid, Arthur, Maïté, Babinet, Marie-Noëlle, Bazin, Nadine, Bellier-Teichmann, Tanja, Bismuth, Corinne, Blain-Pierre, Fabienne, Bloch, Pascal, Bogey, Alice, Bonilla-Guerrero, Julien, Bonsack, Charles, Borrel, Béatrice, Boulon, Yann, Bourlier, Emmanuelle, Bralet, Marie-Cécile, Brana, Armando, Brénugat-Herné, Lindsay, Brousse, Georges, Brunet, Éric, Bulzacka, Eva, Cady, Florian, Callot, Jérémy, Caria, Aude, Cellard, Caroline, Cervello, Sophie, Chambon, Valérian, Charrier, Philippe, Chatelard, Fabienne, Conus, Philippe, Corbière, Marc, Danset-Alexandre, Charlotte, Deegan, Patricia, Delourme, Gwenaelle, Dematteis, Maurice, Demily, Caroline, Destaillats, Jean-Marc, Duboc, Chloé, Dubreucq, Julien, Dubrulle, Aurélie, Dupuis, Marie, Durand, Bernard, Ensenlaz, Xavier, Faraldo, Mégane, Farhat, Sarah-Lise, Favre, Émilie, Favrod, Jérôme, Franck, Nicolas, François, Guillaume, Frankhauser, Adeline, Fredericks, Jennifer, Frobert, Laurent, Fulachier, Delphine, Gabayet, Franck, Gaudelus, Baptiste, Gautier, Corinne, Gayton, Roger, Giordana, Jean-Yves, Baro, Élisabeth Giraud, Gobbo, Julien, Gozlan, Guy, Greacen, Tim, Gremaud, Katya, Grivet, Isabelle, Guy, Cyrielle, Germaneau, Ghina Harika, Hochard, Christophe, Hodé, Yann, Ismailaj, Alban, Jaafari, Nematollah, Jobert, Éliane, Jossserand, Anne-Claire, Jouet, Emmanuelle, Kaliuzhna, Mariia, Khazaal, Yasser, Klein, Rémy, Koubichkine, Alexandra, Kulsa, Mila Kirstie, Lagasse, Stéphanie, Lama-Lama, Pablo, Lambert, Thierry, Lançon, Christophe, Launay, Corinne, Lecardeur, Laurent, Le Cardinal, Patrick, Lecomte, Tania, Leguay, Denis, Leignier, Sylvain, Lindenmayer, Jean-Pierre, Loubières, Céline, Lucas, Thierry, Maillebuau, Mathilde, Malangin, Brigitte, Marsili, Massimo, Martin, Brice, Martin, Juliette, Massoubre, Catherine, Maugiron, Philippe, Medalia, Alice, Melis, Fanny, Meunier-Cussac, Sophie, Morandi, Stéphane, Morin, Laurent, Ngakui, Anne, Nguyen, Alexandra, Oker, Ali, Orens, Sandrine, Pachoud, Bernard, Passerieux, Christine, Pellet, Jacques, Pellet, Joanie, Penn, David, Pennel, Lucie, Périer, Claire-Cécile, Petitjean, François, Peyroux, Élodie, de Pierrefeu, Inès, Planas, Pedro, Plane, Morgane, Pomini, Valentino, Pousthomis, Malgorzata, Prouteau, Antoinette, Quilès, Clélia, Raffard, Stéphane, Rebelle, Sandrine, Reeder, Clare, Regnier, Jennifer, Rengade, Charles-Édouard, Revil, Katia, Ridders, Jean-François, Rigaut, Bérangère, Rivet, Amandine, R-Mercier, Alexandra, Rochet, Cécile, Roelandt, Jean-Luc, Roussel, Céline, Roux, Paul, Salas-Toquero, Caroline, Schoendorff, Marianne, Staedel, Bérénice, Thibaudeau, Élisabeth, Todd, Aurélia, Todoroff, Floriane, Van der Henst, Jean-Baptiste, Vanzetti, Marie, Verdoux, Hélène, Vianin, Pascal, Vidon, Gilles, Willard, Dominique, Wykes, Til, and Younès, Nadia

Published
2018
Full Text
View/download PDF

91. Stigmatization towards electroconvulsive therapy: impact of practical teaching on medical and nursing students

Author

Quiles, Clelia, Sy, Heloïse, and Verdoux, Helene

Abstract

Background: This study explored the impact of theoretical and practical teaching on electro-convulsive therapy (ECT) on medical and nursing students’ stigmatizing attitudes towards ECT and representations of it. Method: Fourth-year medical students and nursing students answered questions from the Questionnaire on Attitudes and Knowledge of ECT (QuAKE) and from the Mental Illness: Clinicians' Attitudes version 2 (MICA v2) scale. The questionnaires were completed before and after observing a 3-hour practical training session in the ECT unit. The endpoint was the impact of practical training as assessed by MICA and QuAKE scores. Multivariate analyses were used to explore the impact of practical training on MICA and QuAKE total scores. Results: Stigmatizing attitudes and representations of both medical and nursing students towards ECT were reduced after practical training (ß =-4.43 [95% CI -6.15 ; -2.70] p = 0.0001). The impact was greater in medical students (ß = -8.03; 95% CI [-10.71; -5.43], p=0.0001) than in nursing students (ß = -2.77; 95% CI [-4.98; to 0.44], p=0.02). Gender, psychiatric history in close persons, and having already followed a psychiatric / ECT course had no independent impact on stigmatizing attitudes towards ECT and representations of it. Conclusion: Practical training in ECT should be given to all health professionals to improve access to it.

Published
2023
Full Text
View/download PDF

93. Obstetric Complications and Age at Onset in Schizophrenia

Author

Verdoux, Helene, primary, Geddes, John R., additional, Takei, Noriyoshi, additional, Lawrie, Stephen M., additional, Bovet, Pierre, additional, Eagles, John M., additional, Heun, Reinhard, additional, McCreadie, Robin G., additional, McNeil, Thomas F., additional, O'Callaghan, Eadbhard, additional, Stober, Gerald, additional, Willinger, Ulrike, additional, Wright, Padraig, additional, and Murray, Robin M., additional

Published
1998
Full Text
View/download PDF

94. A case of lithium neurotoxicity with irreversible cerebellar syndrome

Author

Verdoux, Helene and Bourgeois, Marc L.

Subjects
Lithium -- Adverse and side effects, Brain diseases, Psychology and mental health
Abstract

Lithium carbonate provides a useful and fairly specific form of chemotherapy for manic psychosis and manic-depressive disorders. Side effects involving serious neurological damage are rare. A 31-year-old white male developed irreversible cerebellar syndrome after treatment with lithium. He was admitted to the hospital in a manic state accompanied by delusions, hallucinations and aggressive outbursts fueled by frequent alcoholic bouts. Several trials of various neuroleptics (antipsychotic medications) were carried out unsuccessfully. Five months after admission, he developed a high fever. Physical, laboratory and neurological examinations were negative except for an increase in his white cell count and blood levels of two muscle enzymes. Because neuroleptic malignant syndrome was suspected, he was withdrawn from all neuroleptics. Within three days, temperature and blood levels returned to normal. Lithium therapy was then initiated. Eleven days later he began vomiting and complaining of visual problems. He had difficulty swallowing, and demonstrated symptoms of cerebellar syndrome, including muscle incoordination, hand tremor, vertical eye-rolling, and stiffness of the joints. Again, all physical, laboratory and neurological exams, including computerized tomography scans, were normal. Three months later, magnetic resonance imaging revealed mild cerebellar reduction (atrophy). Despite all rehabilitation efforts he was still unable to walk after one year. His case suggests a possible association between alcoholism, the administration of lithium just after an episode of high fever, and increased risk for susceptibility to cerebellar syndrome. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

97. Psychopharmacology for the Clinician.

Author

Siskind, Dan, Honer, William G., Clark, Scott, Correll, Christoph U., Hasan, Alkomiet, Howes, Oliver, Kane, John M., Kelly, Deanna L., Laitman, Robert, Lee, Jimmy, MacCabe, James H., Myles, Nick, Nielsen, Jimmi, Schulte, Peter F., Taylor, David, Verdoux, Helene, Wheeler, Amanda, and Freudenreich, Oliver

Subjects
EDUCATION of physicians, DRUG therapy for schizophrenia, CONSENSUS (Social sciences), MEDICAL protocols, CLOZAPINE, PSYCHOPHARMACOLOGY, COVID-19 pandemic, ANTIPSYCHOTIC agents
Abstract

The article presents a consensus statement from the Treatment Response and Resistance in Psychosis working group regarding the use of clozapine as treatment of psychiatric disorders like schizophrenia during the COVID-19 pandemic. Other topics include absolute neutrophil count (ANC) monitoring programs for clozapine dispensation, and the recommendations like the reduction of ANC monitoring and the reduction of clozapine dosage if fever and flu-like symptoms appear.

Published
2020
Full Text
View/download PDF

98. EDITORIAL: PSYCHIATRY IN FRANCE.

Author

Verdoux, Helene

Subjects
*PSYCHIATRY, *MENTAL health, *PSYCHIATRISTS, *MEDICAL care research
Abstract

Editorial. Provides a history of psychiatry in France. Implementation of a mental health care organization in France after World War II; Number of registered psychiatrists in France; State of psychiatric research in the country as of June 2003.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results